Fibrinogen A alpha-chain associated amyloidosis: Difference between revisions
Jump to navigation
Jump to search
Line 54: | Line 54: | ||
==Treatment== | ==Treatment== | ||
===Medical Therapy=== | ===Medical Therapy=== | ||
Fibrinogen production is exclusively hepatic. | |||
Isolated renal transplantation as a treatment for renal failure in fibrinogen amyloidosis is of limited value. | |||
===Surgery=== | ===Surgery=== |
Revision as of 20:49, 4 November 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Synonyms and keywords:Fibrinogen amyloidosis
Overview
Historical Perspective
Fibrinogen amyloidosis was first discovered by Dr Merill Benson et al, an American physician, in 1993.[1]
Classification
Pathophysiology
Causes
Epidemiology and Demographics
is emerging as the most common type of all hereditary renal amyloid diseases in the United Kingdom and Europe.
A tertiary US amyloid reference center suggestsfibrinogen A alpha-chain amyloidosis is the leading cause of hereditary renal amyloidosis associated with nephrotic syndrome in the United States.
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Fibrinogen production is exclusively hepatic.
Isolated renal transplantation as a treatment for renal failure in fibrinogen amyloidosis is of limited value.
Surgery
Primary Prevention
Secondary Prevention
References
- ↑ Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R (1993). "Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain". Nat Genet. 3 (3): 252–5. doi:10.1038/ng0393-252. PMID 8097946.